SPOTLIGHT -
Future Phase 3 DUO-E Subgroup Data May Prove ‘Intriguing’ in Endometrial Cancer
Future analyses will look at durvalumab/olaparib for endometrial cancer populations with TP53 and POLE alterations, as well as those with estrogen receptor and progesterone receptor positivity.
Phase 3 DUO-E Study Findings Prove ‘Exciting’ in Advanced Endometrial Cancer
Patients with mismatch repair proficient, newly diagnosed, advanced or recurrent endometrial cancer may have enhanced benefit with the addition of olaparib to durvalumab.
Shannon N. Westin, MD, MPH, Discussed the Wee1 Inhibitor Adavosertib for PARPi-Resistant Ovarian Cancer
CancerNetwork® sat down with Shannon N. Westin, MD, MPH, at the 2021 ASCO Annual Meeting to talk about the use of adavosertib in PARP inhibitor–resistant ovarian cancer.
